Rancoule Chloé, Vallard Alexis, Guy Jean-Baptiste, Espenel Sophie, Diao Peng, Chargari Cyrus, Magné Nicolas
Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis, Avenue Albert Raimond, BP 60008, 42271 Saint-Priest en Jarez, France.
Department of Radiotherapy, Lucien Neuwirth Cancer Institute, 108 bis, Avenue Albert Raimond, BP 60008, 42271 Saint-Priest en Jarez, France; Laboratoire de Radiobiologie Cellulaire et Moléculaire, CNRS UMR 5822, Institut de Physique Nucléaire de Lyon, IPNL, 69622 Villeurbanne, France.
Crit Rev Oncol Hematol. 2017 Aug;116:32-37. doi: 10.1016/j.critrevonc.2017.05.007. Epub 2017 May 20.
The management of Non Small Cell Lung Cancer (NSCLC) brain metastases is challenging, as this frequent complication negatively impacts patients' quality of life, and can be a life-threatening event. Through a review of the literature, we discuss the main therapeutic options and the recent developments that improved (and complicated) the management of NSCLC brain metastases patients. Most current validated approaches are local with exclusive or combined surgery, whole brain radiotherapy (WBRT) and stereotactic radiotherapy (SRT). At the same time, there is a growing role for systemic treatments that might significantly postpone WBRT. Targeted therapies efficacy/toxicity profile remains to be defined but predictive and prognostic molecular factors integration could help to select treatments fully adapted to life expectancy and progression risk.
非小细胞肺癌（NSCLC）脑转移的管理具有挑战性，因为这种常见并发症会对患者的生活质量产生负面影响，并且可能是危及生命的事件。通过对文献的回顾，我们讨论了主要的治疗选择以及改善（和复杂化）NSCLC脑转移患者管理的最新进展。目前大多数经过验证的方法是局部治疗，包括单独或联合手术、全脑放疗（WBRT）和立体定向放疗（SRT）。与此同时，全身治疗的作用越来越大，可能会显著推迟WBRT。靶向治疗的疗效/毒性特征仍有待确定，但整合预测和预后分子因素有助于选择完全适合预期寿命和进展风险的治疗方法。
